The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target.
The growth of solid tumours requires a blood supply provided by re-modeling of existing blood vessel endothelium (angiogenesis). Little is known about transcription regulators which are specific for the control of tumour angiogenesis. The proto-oncogene LMO2 encodes a LIM domain transcription regula...
Main Authors: | Yamada, Y, Pannell, R, Forster, A, Rabbitts, T |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2002
|
Similar Items
-
The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice.
by: Yamada, Y, et al.
Published: (2000) -
The transcription factor complex LMO2/TAL1 regulates branching and endothelial cell migration in sprouting angiogenesis
by: Yoshihiro Yamada, et al.
Published: (2022-05-01) -
The hepatitis C virus internal ribosome entry site facilitates efficient protein synthesis in blood vessel endothelium during tumour angiogenesis.
by: Chung, G, et al.
Published: (2003) -
LIM Domain Only 2 Regulates Endothelial Proliferation, Angiogenesis, and Tissue Regeneration
by: Shu Meng, et al.
Published: (2016-10-01) -
Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer
by: Yingying Li, et al.
Published: (2022-03-01)